Aardvark Therapeutics (AARD) vs Adicet Bio (ACET)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adicet Bio (ACET) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 77.8% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $20.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | ACET |
|---|---|---|
| Share price | $0.9226 | $2.14 |
| Market cap | $20.20M | $20.03M |
| 1-day change | -7.74% | -13.01% |
| YTD return | -92.97% | -74.58% |
| 1-year return | -90.15% | -77.78% |
| 5-year return | — | -98.58% |
| EPS (TTM) | $-3.33 | $-7.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-57.59M | $-116.80M |
| 52-week high | $16.60 | $11.15 |
| 52-week low | $0.90 | $2.12 |
| Distance from 52-week high | -94.44% | -80.81% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1104.21% | +1527.57% |
| Average volume | 643.53K | 271.05K |
| Shares outstanding | 21.89M | 9.36M |
| Employees | 28 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed AARD by 12.4 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
AARD vs ACET FAQ
Which is bigger, Aardvark Therapeutics or Adicet Bio?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $20.03M for Adicet Bio (ACET).
Which stock has performed better over the past year, AARD or ACET?
ACET returned -77.78% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Adicet Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.